Opinion statement All MPM patients with a good performance status should be considered
for enrollment on clinical trials. With that said, the standard frontline therapy for fit MPM …

Systemic chemotherapy with pemetrexed and cisplatin has been the cornerstone of
treatment for advanced pleural mesothelioma since 2004, when the EMPHACIS trial …

Background Optimal therapy for malignant pleural mesothelioma (MPM) remains unclear.
We compared overall survival in patients with MPM after various multimodal treatment …

Background Nintedanib targets VEGF receptors 1–3, PDGF receptors α and β, FGF
receptors 1–3, and Src and Abl kinases, which are all implicated in malignant pleural …

Pleural mesothelioma (PM) remains a malignancy with poor prognosis. Despite initial
disappointing response rates to single-agent chemotherapy, upfront platinum and anti-folate …

Methods We designed a phase 1 safety run-in of the combination of anetumab ravtansine
(6.5 mg/kg iv q3weeks) and pembrolizumab (200 mg, IV q3weeks) followed by a phase 2 …

The pemetrexed-cisplatin chemotherapy is standard of care in first-line (FL) treatment of
malignant pleural mesothelioma (MPM). The second-line (SL) chemotherapy is considered …

Objectives A recent Phase III trial, the MAPS (Mesothelioma Avastin Cisplatin Pemetrexed
Study), investigated the addition of bevacizumab to cisplatin plus pemetrexed in malignant …

BACKGROUND: An expanded access program (EAP) provided patient access to
pemetrexed prior to its commercial availability. The current report consists of US patients in …

Background MPM is an aggressive malignancy of increasing prevalence and poor
prognosis. At relapse after platinum-based (pb) CT, single agent CT is commonly used and …